pulmocide limited
pulmocide limited Company Information
Company Number
06182024
Next Accounts
Sep 2025
Shareholders
jeito slp
sr one capital fund i aggregator lp
View AllGroup Structure
View All
Industry
Research and experimental development on biotechnology
Registered Address
office suite 3.01, 44 southampton buildings, london, WC2A 1AP
Website
www.pulmocide.compulmocide limited Estimated Valuation
Pomanda estimates the enterprise value of PULMOCIDE LIMITED at £0 based on a Turnover of £0 and 1.35x industry multiple (adjusted for size and gross margin).
pulmocide limited Estimated Valuation
Pomanda estimates the enterprise value of PULMOCIDE LIMITED at £0 based on an EBITDA of £-37.4m and a 5.31x industry multiple (adjusted for size and gross margin).
pulmocide limited Estimated Valuation
Pomanda estimates the enterprise value of PULMOCIDE LIMITED at £23.3m based on Net Assets of £13m and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pulmocide Limited Overview
Pulmocide Limited is a live company located in london, WC2A 1AP with a Companies House number of 06182024. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in March 2007, it's largest shareholder is jeito slp with a 18.6% stake. Pulmocide Limited is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pulmocide Limited Health Check
Pomanda's financial health check has awarded Pulmocide Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 2 areas for improvement. Company Health Check FAQs
2 Strong
0 Regular
2 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Pulmocide Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Pulmocide Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Pulmocide Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Pulmocide Limited
- - Industry AVG
Employees
with 9 employees, this is below the industry average (54)
- - Pulmocide Limited
- - Industry AVG
Pay Structure
on an average salary of £178.6k, the company has a higher pay structure (£83.1k)
- - Pulmocide Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- - Pulmocide Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Pulmocide Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Pulmocide Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Pulmocide Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 57 weeks, this is more cash available to meet short term requirements (30 weeks)
- - Pulmocide Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 36.3%, this is a lower level of debt than the average (53.1%)
- - Pulmocide Limited
- - Industry AVG
PULMOCIDE LIMITED financials
Pulmocide Limited's latest turnover from December 2023 is 0 and the company has net assets of £13 million. According to their latest financial statements, Pulmocide Limited has 9 employees and maintains cash reserves of £8.2 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | 10,143,325 | 1,543,686 | |||||||||||||
| Operating Profit | -37,444,182 | -26,295,171 | -12,022,068 | -10,143,325 | -9,194,153 | -10,056,754 | -13,189,117 | -6,041,974 | -1,543,686 | ||||||
| Interest Payable | 413,783 | 4,545,294 | 3,734,195 | 3,906,753 | 2,898,947 | 1,794,914 | |||||||||
| Interest Receivable | 8,077 | ||||||||||||||
| Pre-Tax Profit | -30,591,068 | -37,021,740 | -12,435,851 | -14,688,619 | -12,928,348 | -13,408,677 | -16,088,064 | -7,836,888 | -9,825,278 | -5,257,373 | -1,543,686 | ||||
| Tax | 4,935,074 | 6,008,629 | 2,210,815 | 1,810,224 | 1,694,355 | 2,133,152 | 3,840,573 | 2,132,401 | 1,121,665 | ||||||
| Profit After Tax | -25,655,994 | -31,013,111 | -10,225,036 | -12,878,395 | -11,233,993 | -11,275,525 | -12,247,491 | -5,704,487 | -8,703,613 | -5,257,373 | -1,543,686 | ||||
| Dividends Paid | |||||||||||||||
| Retained Profit | -25,655,994 | -31,013,111 | -10,225,036 | -12,878,395 | -11,233,993 | -11,275,525 | -12,247,491 | -5,704,487 | -8,703,613 | -5,257,373 | -1,543,686 | ||||
| Employee Costs | 1,607,842 | 1,261,115 | 967,882 | 2,396,930 | 1,845,276 | 1,555,260 | 1,316,994 | 1,102,621 | 396,336 | ||||||
| Number Of Employees | 9 | 7 | 6 | 9 | 10 | 10 | 11 | 12 | 13 | 11 | 4 | ||||
| EBITDA* | -37,427,564 | -26,284,897 | -12,014,659 | -10,122,780 | -9,174,982 | -10,032,293 | -13,126,030 | -5,959,817 | -1,523,749 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 49,223 | 39,910 | 23,806 | 8,449 | 28,975 | 48,146 | 48,197 | 96,204 | 165,564 | 241,875 | 209,978 | ||||
| Intangible Assets | |||||||||||||||
| Investments & Other | 1,384,906 | 763,200 | 407,914 | 234,055 | 41,716 | 2 | 2 | 2 | |||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 1,434,129 | 803,110 | 431,720 | 242,504 | 70,691 | 48,148 | 48,199 | 96,206 | 165,564 | 241,875 | 209,978 | ||||
| Stock & work in progress | |||||||||||||||
| Trade Debtors | |||||||||||||||
| Group Debtors | 4,119,223 | ||||||||||||||
| Misc Debtors | 6,711,094 | 10,403,992 | 4,623,887 | 2,338,733 | 2,288,644 | 2,434,530 | 3,158,419 | 442,708 | 602,541 | 345,196 | 347,181 | ||||
| Cash | 8,170,516 | 43,840,064 | 35,509,633 | 5,903,046 | 12,834,325 | 5,161,431 | 12,958,485 | 13,255,425 | 3,230,581 | 7,057,841 | 5,112,837 | ||||
| misc current assets | |||||||||||||||
| total current assets | 19,000,833 | 54,244,056 | 40,133,520 | 8,241,779 | 15,122,969 | 7,595,961 | 16,116,904 | 13,698,133 | 3,833,122 | 7,403,037 | 5,460,018 | ||||
| total assets | 20,434,962 | 55,047,166 | 40,565,240 | 8,484,283 | 15,193,660 | 7,644,109 | 16,165,103 | 13,794,339 | 3,998,686 | 7,644,912 | 5,669,996 | ||||
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 2,316,327 | 3,357,680 | 1,977,458 | 1,756,239 | 951,752 | 665,963 | 1,825,608 | 807,890 | 1,212,564 | 257,961 | 73,301 | ||||
| Group/Directors Accounts | 144,551 | 733,349 | 128,055 | ||||||||||||
| other short term finances | 3,873,455 | 10,726,569 | |||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 1,077,867 | 2,525,867 | 1,169,357 | 11,136,852 | 562,019 | 537,260 | 751,932 | 289,671 | 290,794 | 166,784 | 140,381 | ||||
| total current liabilities | 7,412,200 | 17,343,465 | 3,274,870 | 12,893,091 | 1,513,771 | 1,203,223 | 2,577,540 | 1,097,561 | 1,503,358 | 424,745 | 213,682 | ||||
| loans | 48,834,408 | 35,935,461 | 18,000,000 | 14,000,000 | 7,000,000 | ||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | 64,029,182 | 68,322,786 | 51,618,472 | ||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | 64,029,182 | 68,322,786 | 51,618,472 | 48,834,408 | 35,935,461 | 18,000,000 | 14,000,000 | 7,000,000 | |||||||
| total liabilities | 7,412,200 | 17,343,465 | 3,274,870 | 76,922,273 | 69,836,557 | 52,821,695 | 51,411,948 | 37,033,022 | 19,503,358 | 14,424,745 | 7,213,682 | ||||
| net assets | 13,022,762 | 37,703,701 | 37,290,370 | -68,437,990 | -54,642,897 | -45,177,586 | -35,246,845 | -23,238,683 | -15,504,672 | -6,779,833 | -1,543,686 | ||||
| total shareholders funds | 13,022,762 | 37,703,701 | 37,290,370 | -68,437,990 | -54,642,897 | -45,177,586 | -35,246,845 | -23,238,683 | -15,504,672 | -6,779,833 | -1,543,686 |
| Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -37,444,182 | -26,295,171 | -12,022,068 | -10,143,325 | -9,194,153 | -10,056,754 | -13,189,117 | -6,041,974 | -1,543,686 | ||||||
| Depreciation | 16,618 | 10,274 | 7,409 | 20,545 | 19,171 | 24,461 | 63,087 | 82,157 | 85,664 | 74,528 | 19,937 | ||||
| Amortisation | |||||||||||||||
| Tax | 4,935,074 | 6,008,629 | 2,210,815 | 1,810,224 | 1,694,355 | 2,133,152 | 3,840,573 | 2,132,401 | 1,121,665 | ||||||
| Stock | |||||||||||||||
| Debtors | 426,325 | 5,780,105 | 2,335,243 | 50,089 | -145,886 | -723,889 | 2,715,711 | -159,833 | 257,345 | -1,985 | 347,181 | ||||
| Creditors | -1,041,353 | 1,380,222 | 1,025,706 | 804,487 | 285,789 | -1,159,645 | 1,017,718 | -404,674 | 954,603 | 184,660 | 73,301 | ||||
| Accruals and Deferred Income | -1,448,000 | 1,356,510 | 607,338 | 10,574,833 | 24,759 | -214,672 | 462,261 | -1,123 | 124,010 | 26,403 | 140,381 | ||||
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | -35,408,168 | -23,319,641 | -10,506,043 | 3,016,675 | -7,024,193 | -8,549,569 | -10,521,189 | -4,073,380 | -1,657,248 | ||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 621,706 | 355,286 | 366,198 | 192,339 | 41,714 | 2 | |||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -588,798 | 605,294 | 128,055 | ||||||||||||
| Other Short Term Loans | -6,853,114 | 10,726,569 | |||||||||||||
| Long term loans | -48,834,408 | 12,898,947 | 17,935,461 | 4,000,000 | 7,000,000 | 7,000,000 | |||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | -68,322,786 | -4,293,604 | 16,704,314 | 51,618,472 | |||||||||||
| share issue | |||||||||||||||
| interest | -413,783 | -4,545,294 | -3,734,195 | -3,898,676 | -2,898,947 | -1,794,914 | |||||||||
| cash flow from financing | -6,466,857 | 42,758,305 | 33,549,789 | -9,755,596 | 14,738,801 | 230,172 | 10,239,329 | 14,111,023 | 3,978,774 | 7,021,226 | 7,000,000 | ||||
| cash and cash equivalents | |||||||||||||||
| cash | -35,669,548 | 8,330,431 | 22,675,308 | -6,931,279 | 7,672,894 | -7,797,054 | -296,940 | 10,024,844 | -3,827,260 | 1,945,004 | 5,112,837 | ||||
| overdraft | |||||||||||||||
| change in cash | -35,669,548 | 8,330,431 | 22,675,308 | -6,931,279 | 7,672,894 | -7,797,054 | -296,940 | 10,024,844 | -3,827,260 | 1,945,004 | 5,112,837 |
pulmocide limited Credit Report and Business Information
Pulmocide Limited Competitor Analysis
Perform a competitor analysis for pulmocide limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other established companies, companies in WC2A area or any other competitors across 12 key performance metrics.
pulmocide limited Ownership
PULMOCIDE LIMITED group structure
Pulmocide Limited has 1 subsidiary company.
pulmocide limited directors
Pulmocide Limited currently has 9 directors. The longest serving directors include Dame Catherine Bingham (Oct 2013) and Mr Daniel Burgess (Mar 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dame Catherine Bingham | 59 years | Oct 2013 | - | Director | |
| Mr Daniel Burgess | United States | 63 years | Mar 2017 | - | Director |
| Mr Matthew Foy | 44 years | Mar 2017 | - | Director | |
| Dr Fiona Mash | England | 53 years | Sep 2020 | - | Director |
| Mrs Sabine Dandiguian | France | 64 years | May 2021 | - | Director |
| Sabine Dandiguian | France | 64 years | May 2021 | - | Director |
| Kabeer Aziz | United States | 35 years | May 2021 | - | Director |
| Mr James Meyers | England | 61 years | Sep 2021 | - | Director |
| Mr Alexander Pasteur | United Kingdom | 54 years | Apr 2023 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
-37.4m
+42%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
13m
-0.65%
total assets
20.4m
-0.63%
cash
8.2m
-0.81%
net assets
Total assets minus all liabilities
pulmocide limited company details
company number
06182024
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
March 2007
age
18
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
office suite 3.01, 44 southampton buildings, london, WC2A 1AP
Bank
BARCLAYS BANK PLC
Legal Advisor
COVINGTON & BURLING LLP
pulmocide limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to pulmocide limited.
pulmocide limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PULMOCIDE LIMITED. This can take several minutes, an email will notify you when this has completed.
pulmocide limited Companies House Filings - See Documents
| date | description | view/download |
|---|
